Free Trial

VolitionRx (VNRX) Competitors

VolitionRx logo
$0.70 +0.05 (+8.36%)
Closing price 04:00 PM Eastern
Extended Trading
$0.68 -0.01 (-2.14%)
As of 06:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VNRX vs. TRDA, CRVS, PVLA, TSVT, TNXP, ALLO, INZY, ALDX, CADL, and ACB

Should you be buying VolitionRx stock or one of its competitors? The main competitors of VolitionRx include Entrada Therapeutics (TRDA), Corvus Pharmaceuticals (CRVS), Palvella Therapeutics (PVLA), 2seventy bio (TSVT), Tonix Pharmaceuticals (TNXP), Allogene Therapeutics (ALLO), Inozyme Pharma (INZY), Aldeyra Therapeutics (ALDX), Candel Therapeutics (CADL), and Aurora Cannabis (ACB). These companies are all part of the "pharmaceutical products" industry.

VolitionRx vs. Its Competitors

Entrada Therapeutics (NASDAQ:TRDA) and VolitionRx (NYSE:VNRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

Entrada Therapeutics has a net margin of 14.39% compared to VolitionRx's net margin of -2,321.14%. Entrada Therapeutics' return on equity of 5.84% beat VolitionRx's return on equity.

Company Net Margins Return on Equity Return on Assets
Entrada Therapeutics14.39% 5.84% 4.61%
VolitionRx -2,321.14%N/A -163.39%

Entrada Therapeutics has a beta of -0.11, suggesting that its stock price is 111% less volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.

Entrada Therapeutics presently has a consensus price target of $25.67, suggesting a potential upside of 302.30%. VolitionRx has a consensus price target of $3.50, suggesting a potential upside of 400.00%. Given VolitionRx's higher possible upside, analysts plainly believe VolitionRx is more favorable than Entrada Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entrada Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.25
VolitionRx
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.00

In the previous week, Entrada Therapeutics had 7 more articles in the media than VolitionRx. MarketBeat recorded 10 mentions for Entrada Therapeutics and 3 mentions for VolitionRx. Entrada Therapeutics' average media sentiment score of 0.37 beat VolitionRx's score of 0.03 indicating that Entrada Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Entrada Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
VolitionRx
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 8.1% of VolitionRx shares are owned by institutional investors. 7.6% of Entrada Therapeutics shares are owned by insiders. Comparatively, 10.4% of VolitionRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Entrada Therapeutics has higher revenue and earnings than VolitionRx. VolitionRx is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Entrada Therapeutics$210.78M1.15$65.63M$0.817.88
VolitionRx$1.31M55.63-$35.32M-$0.27-2.59

Summary

Entrada Therapeutics beats VolitionRx on 12 of the 16 factors compared between the two stocks.

Get VolitionRx News Delivered to You Automatically

Sign up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VNRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VNRX vs. The Competition

MetricVolitionRxDiagnostic substances IndustryMedical SectorNYSE Exchange
Market Cap$72.79M$18.62M$5.57B$20.65B
Dividend YieldN/AN/A4.23%3.65%
P/E Ratio-1.94N/A28.6127.29
Price / Sales55.6319.48411.3153.19
Price / CashN/AN/A36.0222.28
Price / Book-6.360.018.234.60
Net Income-$35.32M-$15.34M$3.23B$995.22M
7 Day Performance5.90%-2.80%-0.01%-0.80%
1 Month Performance-2.11%-12.30%5.60%3.55%
1 Year Performance8.33%-43.04%26.54%7.35%

VolitionRx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VNRX
VolitionRx
2.1035 of 5 stars
$0.70
+8.4%
$3.50
+400.0%
-1.0%$72.79M$1.31M-1.9480News Coverage
Gap Up
TRDA
Entrada Therapeutics
3.3089 of 5 stars
$6.97
-3.6%
$25.67
+268.2%
-64.3%$274.40M$172.22M8.61110
CRVS
Corvus Pharmaceuticals
2.8376 of 5 stars
$3.90
-1.3%
$15.00
+284.6%
+108.5%$269.27MN/A-3.9830Positive News
PVLA
Palvella Therapeutics
2.5116 of 5 stars
$24.90
+3.2%
$46.29
+85.9%
N/A$266.66M$42.81M-2.06N/A
TSVT
2seventy bio
N/A$5.00
flat
$5.00
N/A$266.15M$48.37M-2.69440
TNXP
Tonix Pharmaceuticals
2.6677 of 5 stars
$35.44
-0.1%
$585.00
+1,550.7%
-25.9%$261.03M$10.09M-0.0250Gap Up
ALLO
Allogene Therapeutics
3.6452 of 5 stars
$1.16
-2.5%
$8.44
+628.0%
-58.4%$260.29M$20K-0.94310Positive News
INZY
Inozyme Pharma
3.4973 of 5 stars
$4.00
flat
$11.75
+193.8%
N/A$258.25MN/A-2.3750
ALDX
Aldeyra Therapeutics
2.5715 of 5 stars
$4.35
+1.2%
$9.50
+118.4%
+25.5%$257.55MN/A-4.4810News Coverage
Positive News
CADL
Candel Therapeutics
2.4779 of 5 stars
$4.99
-2.2%
$22.00
+340.9%
-5.6%$255.53MN/A-3.7260Analyst Revision
ACB
Aurora Cannabis
0.2928 of 5 stars
$4.43
-2.4%
N/A-26.3%$255.21M$246.72M40.271,130

Related Companies and Tools


This page (NYSE:VNRX) was last updated on 7/16/2025 by MarketBeat.com Staff
From Our Partners